These benefits set employees up with the resources and access to manage their health efficiently and proactively while giving employers financial savings throughout the year. The post The Benefits Hierarchy of Needs: Why Employers & Payers Should Prioritize Gut Health Benefits appeared first on MedCity News.
Cigna’s self-insured clients now have the option to offer the Hinge Health platform to its employees. Through the platform, patients gain virtual access to physical therapists, health coaches, real-time guidance and a wearable pain relief device. The post Hinge Health Launches MSK Collaboration with Cigna Healthcare appeared first on MedCity News.
New moms all over social media are breaking down their incredibly expensive hospital bills after giving birth. So why is giving birth so pricey in the U.S.? And given the Trump administration’s anti-abortion, pro-natalist policies, is anything on the table to make having a child more affordable? KFF Health News video producer Hannah Norman spoke…
If HSAs and FSAs were functioning as originally intended, the rising out-of-pocket costs faced by most Americans would be met with increased financial fluency and agency. The post HSAs And FSAs Were Designed to Give Consumers Control and Clarity of Their Healthcare Spending — Why Isn’t This Happening? appeared first on MedCity News.
KFF Health News chief rural correspondent Sarah Jane Tribble discussed the $50 billion rural health fund authorized by the recent Republican megabill on Daily Yonder’s “The Yonder Report” on July 31. Click here to hear Tribble on “The Yonder Report.” Read Tribble’s “$50B Rural Health ‘Slush Fund’ Faces Questions, Skepticism.” Céline Gounder, KFF Health News’…
Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing. The post Novartis Tries Again in Huntington’s, Putting Up…
McKesson is paying $2.49 billion in cash for a controlling interest in Florida Cancer Specialists’ management services organization
Organon said OG-6219 did not beat a placebo in a mid-stage clinical trial whose main goal was to measure the change in pelvic pain caused by endometriosis. The twice-daily pill came from Organon’s 2021 acquisition of Forendo Pharma. The post Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test appeared first on…
That is the title of my recent publication with co-authors Andrea Chung, Sachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard Clarkson Alsfeld, Sanjana Muthukrishnan and Anik R Patel, Gunjan L Shah, Richard T Maziarz. The abstract is below. CAR T-cell therapy has shown curative potential for patients with diffuse large B-cell lymphoma (DLBCL) and other malignancies,…
Danish Qureshi, CEO of Zarminali, plans to open pediatric clinics in 30 states over the course of the next 36 months